- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Undervalued based on future growth
U.S. Pharmaceuticals & Biotech Undervalued based on future growth
Results
12
Companies which can be considered undervalued when accounting for expected future growth (PEG under 0.8)
12 companies
ACADIA Pharmaceuticals
Market Cap: US$4.1b
A biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States.
ACAD
US$23.60
7D
-1.5%
1Y
49.0%
ADMA Biologics
Market Cap: US$3.8b
A biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.
ADMA
US$15.98
7D
1.8%
1Y
-17.2%
Organon
Market Cap: US$2.7b
Develops and delivers health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, Latin America, the Middle East, Russia, Africa, and internationally.
OGN
US$10.54
7D
1.7%
1Y
-46.4%
Harmony Biosciences Holdings
Market Cap: US$1.9b
A commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States.
HRMY
US$32.07
7D
-0.7%
1Y
-15.2%
Collegium Pharmaceutical
Market Cap: US$1.1b
A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.
COLL
US$34.90
7D
-2.0%
1Y
-7.6%
CorMedix
Market Cap: US$879.7m
A biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States.
CRMD
US$11.44
7D
-1.3%
1Y
52.3%
SIGA Technologies
Market Cap: US$670.9m
A commercial-stage pharmaceutical company, focuses on the health security market in the United States.
SIGA
US$9.06
7D
0.8%
1Y
13.1%
Abeona Therapeutics
Market Cap: US$281.0m
A clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases.
ABEO
US$5.51
7D
-3.0%
1Y
-4.3%
Protalix BioTherapeutics
Market Cap: US$162.7m
A biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system.
PLX
US$1.96
7D
0.5%
1Y
81.5%
Atara Biotherapeutics
Market Cap: US$86.4m
Engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and the United Kingdom.
ATRA
US$12.97
7D
12.7%
1Y
71.8%
Earth Science Tech
Market Cap: US$54.2m
Together with its subsidies, focuses on health and wellness industry.
ETST
US$0.18
7D
-2.6%
1Y
8.8%
Neuphoria Therapeutics
Market Cap: US$18.5m
A clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia.
NEUP
US$11.04
7D
-11.8%
1Y
n/a